Uncategorised

006 Bremelanotide for Hypoactive Sexual Desire Disorder: Integrated Subgroup Analysis According to FSFI Total Score at Screening

 

Bremelanotide (BMT) is a melanocortin receptor 4 agonist that is being investigated as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical studies indicate that BMT has greater efficacy than placebo for treatment of HSDD. The objective of this integrated analysis was to investigate BMT efficacy vs placebo for subjects according to pre-specified patient reported outcome (PRO) definitions of HSDD at baseline.

006 Bremelanotide for Hypoactive Sexual Desire Disorder: Integrated Subgroup Analysis According to FSFI Total Score at Screening

2018-06

The Journal of Sexual Medicine

https://www.jsm.jsexmed.org/article/S1743-6095(18)30196-6/fulltext?rss=yes

Leave a Reply